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Summary  
There is a great need for new treatments in certain pathologies such as cancer or 
resistant infections. Among some of the most promising novel therapies is gene therapy, 
but it faces serious problems to overcome before using viral vectors into the clinic. To 
solve some of those problems viral gene therapy vectors are recently combined with 
stem cells in cell therapy approaches. However, as they are complicated cells to grow 
with standard tissue culture methods and culture media, this approach has to be 
improved previously to move into manufacturing for clinical trials.  
Synthetic gene-delivery agents such as polymers, although safer than viruses, 
generally do not possess the required efficacy. Dendrimers are three-dimensional, 
highly branched, synthetic polymers with a well-defined chemical structure. In 
particular, PAMAM (poly(amidoamine)) dendrimers have been extensively investigated 
for their biological applications and they have shown clinically-relevant carrier 
properties that could be used for gene or cell therapy purposes. This is facilitated by 
controlling charge and functionality through the choice of peripheral groups, and size 
through generation number and PEGylation. PEG (poly(ethylene glycol)) reduces 
toxicity, improves water solubility, decreases enzymatic degradation, and leads to 
improved biodistributions characteristic.  
Moreover, it has been shown that PAMAM dendrimers can facilitate antibiotic 
localization also inside bacteria, and so, they can be used to enhance the antimicrobial 
activity. Also, they could be highly toxic to certain bacterias themselves by interacting 
and promoting disruption of the cytoplasmatic membrane. By controlling the size and 
PEGylation degree of the PAMAM dendrimers we can modulate the interactions with 
the bacterial surface and their killing activity, lowering the cytotoxicity to the host cells. 
Therefore, PAMAM dendrimers appear as promising antimicrobial agents that are less 
likely to induce bacterial resistance compared to standard antibiotics.  
Here we study the biomedical properties of PAMAM-derived dendrimers on their 
influence on the bacterial and cellular growth. Our results show that, although the 
PAMAM dendrimer completely covered with PEG diminished the pseudomonas growth 
and it has potential to be employed as an antibacterial agent, in the case of mesechymal 
stem cells, the cell growth is increased without altering their pluripotenciality patterns, 
and it could be of great help for the future cell therapy approaches.  
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 PART I: INTRODUCTION 
  
1. GENE AND CELL THERAPIES  
1.1 Development and evolution   
Gene therapy aims to treat both genetic and infectious diseases by restoring, 
modifying or enhancing cellular functions through the introduction of new genetic 
material into the appropriate cells in the body. While traditional drug therapies involve 
the administration of chemicals that have been manufactured outside the body, gene 
therapy takes a very different approach: directing a patient's own cells to produce and 
deliver a therapeutic agent. Gene therapy protocols were originally designed to correct 
inheritable disorders, such as cystic fibrosis, Gaucher's disease, and Duchenne muscular 
dystrophy (Dekker,3).  
Of the two potential strategies for gene therapy, the ex-vivo and the in- vivo, the ex-
vivo (cell-based delivery) strategy allows a wider range of therapies. In this type, cells 
(especially stem cells) would be extracted from patients, transfected with the therapeutic 
gene, grown in culture, and reimplanted in the patient. In the in-vivo (direct delivery) 
approach, genes are administered directly into the patient to transduce the cells in-vivo; 
this delivery method is fairly imprecise and limited to the specific types of human cells 
that the vector can reach (Vetrini, et al,9).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.1. Strategies for Delivering Therapeutic Transgenes into Patients 
(Dekker,3). 
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The first approved gene therapy clinical protocol began in September 1990, using 
retroviral vectors to introduce copies of the adenosine deaminase gene into T cells from 
a patient with adenosine deaminase deficiency. However, clinical progress has been 
slow. In 2002, over 600 clinical protocols have been approved worldwide, incorporating 
over 3500 patients (The Journal of Gene Medicine). A major setback for the field 
occurred in September 1999, when a man died from a massive immune reaction to the 
Ad5 vector that was used to deliver a deficient gene. Moreover, in that same year three 
patients suffering from a severe combined immunodeficiency disorder (SCID-XI) 
developed leukemia as a result of the gene-transfer procedure. This trial reflects the path 
that gene therapy followed: success, but with some complications (Dekker,3).  
Although it was conceived as a therapeutic modality for genetic disorders, over 60% 
of these trials have been directed to the treatment of cancer, reflecting the need for novel 
therapies in this field (The Journal of Gene Medicine). Cancer represents an enormous 
biomedical challenge for gene therapy and drug delivery. Tumors are caused as a 
consequence of mutations in the genome by addition, deletion or change in 
chromosomal pattern. Ideally, the goal of any cancer therapy is to selectively target and 
destroy diseased tissue while sparing the surrounding healthy tissue. Over the past three 
decades, cancer diagnosis, surgery and treatment have improved greatly, but traditional 
therapies (chemotherapy and radiotherapy) are still insufficient (Agarwal, et al,10).  
 
 
 
 
 
 
 
 
In an attempt to solve this problem, new and more specific therapies exclusively 
targeted against cancer cells are currently being developed (Vetrini, et al,9; Pandita, et 
al,11; Li, et al,12; Niidome, et al,13). One of the key problems in gene therapy is the 
efficient delivery of therapeutic transgenes to pathological sites, upon systemic injection 
of the vector (Flint,1; Dekker,3). In this context, the ideal vector should show high 
expression levels, tissue selectivity, and ability to avoid immune response after vector 
re-administration or over long time periods. Amongst all the commonly used vectors, 
Figure 1.2. Indications 
addressed by Gene Therapy 
Clinical Trials (The Journal 
of Gene Medicine, 2012) 
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none meet the mentioned requirements.  For that reason, development of new vectors is 
pivotal for the development of gene therapy (Wolinsky, et al,6; Vetrini, et al,9; Agarwal, 
et al,10; Li, et al,12; Niidome, et al,13; Chen, et al,14).  
Tumours are composed of both malignant and normal cells. The “benign” cell-types 
include endothelial cells forming blood vessels, infiltrating inflammatory cells, and 
stroma. Stromal components provide factors and structural support for malignant cells. 
The formation of tumour stroma closely resembles wound healing and scar formation 
that increase proliferation of mesenchymal stem cells (MSCs) (Dekker,3; Barry,7; 
Pandita, et al,11). Some groups have hypothesized that exogenously administrated 
MSCs would preferentially go to damaged areas independently of the pathology, and in 
the case of tumours they would engraft at the tumor site and contribute to the population 
of the tumour stroma (Santos, et al,15). Based on that hypothesis, MSCs have been 
recently used as vectors to carry therapeutic genes specifically into tumoral areas.  
  
1.2 Vectors for Delivery  
As the success of gene therapy is highly dependent on the delivery vector, research in 
this field has been focused on the development of a suitable delivery system. Two most 
important criteria for a viable gene delivery vector are safety and efficacy: it must not 
elicit an immune response, must not be infectious and must not cause mutagenesis due 
to improper gene insertion, while incorporating sufficient functionality to overcome the 
multitude cellular and extracellular barriers to gene transfer. The first barrier is cellular 
uptake, where the vector must associate with the cell surface; once inside the cell, the 
gene must be released from the endosomes and finally it must be able to overcome the 
nuclear membrane and enter the nucleus.  
Currently the most common and efficient delivery systems are viruses. Major safety 
concerns, however, such as high toxicity and immunogenicity, have limited their 
general use. Investigators of non-viral delivery systems have shown marked 
improvements in efficiency (Vetrini, et al,9; Niidome, et al,13).   
 
 
 
 
 
 
Figure 1.3. Vectors used 
in Gene Therapy Clinical 
Trials (The Journal of 
Gene Medicine, 2012) 
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1.2.1. Viral and cellular Vectors:  
Viral gene delivery systems exploit the natural mechanisms evolved by different 
viruses for cellular entry and gene transfer. However, of the virus-based vector systems 
developed thus far, none are optimal and each system displays advantages and 
disadvantages characteristic of each virus (Dekker,3; Marvaniya, et al,4; Wolinsky, et 
al,6; Agarwal, et al,10; Tomalia, et al,16; Flint,17; Biasco, et al,18). In general, the 
genetic material of the virus is manipulated to carry a copy of the desired gene as well 
as a promoter. The promoter determines whether the gene functions within the cell or 
not. A drug usually activates the promoter, which in turn, activates the gene. The 
activated gene is then translated into proteins. The safety concerns (retention in the 
liver, immunogenicity, oncogenicity, etc.) and difficult large-scale production limits the 
usefulness of recombinant viral vectors (Flint,1; Dekker,3; Biasco, et al,18).   
 
 
 
 
 
 
 
 
     
Mammalian cells (fibroblasts, hepatocytes, mesothelial cells, myoblast, neuronal cells, 
etc) have been proposed as new vector systems, because of their properties with regard 
to immune recognition and toxicity. Some studies suggest that bone marrow cells could 
differentiate widely in different tissues and form hepatic cells, cardiomyocytes, 
neurones, etc (Orkin, et al,19; Morrison,20).  
Mesenchymal stem cells (MSCs) have been studied as vehicles for gene and cellular 
therapy because they are easy to extract from bone marrow (Flores-Figueroa, et al,21; 
22) and to recover organs with just a small population expressing the corrected gene. 
That is why this new field has been named “regenerative therapy” (Pomerantz, et al,23). 
There are hundreds of clinical trials ongoing using MSCs under the common hypothesis 
that MSCs are able to cure and regenerate the damaged areas independently on the 
pathology of study (Bobis, et al,24).  
Figure 1.4. Retroviral life 
cycle (Flint,1).  
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Some groups hypothesized that exogeneous administered mesenchymal stem cells 
(MSCs) would contribute to tumour stroma formation and thus could transport 
substances in a therapeutic context. Tumour stroma formation can be considered 
functionally analogous to the scar formation process undergone following tissue 
damage, both processes involving high MSC proliferation (Mackenzie, et al,25). 
Therefore, such cells could be used as a virus transporter directed specifically to 
different pathologies.  
 
1.2.2. Non-Viral Vectors  
Besides virus-mediated gene-delivery systems, there are several nonviral options for 
direct gene delivery that are attractive alternatives for improved safety, greater 
flexibility and ease of manufacturing. The simplest method is the direct introduction of 
therapeutic DNA into target cells. A number of barriers must be overcome: it must be 
protected from degradation, it must cross the cell membranes and when chemical 
methods are used, the complexes formed by the DNA and by the non-viral vectors must 
be released from the formed endosomes and decomplexation must occur. Also, it can 
only be done in certain tissues and requires large amounts of DNA (Marvaniya, et al,4; 
Wang, et al,26; Maruyama-Tabata, et al,27; Fant, et al,28; Qi, et al,29).   
Other approaches use other vectors to transport DNA to the cell: synthetic nonviral 
vectors. Synthetic vectors are more versatile: their chemical and physical properties, for 
instance, allow the packing of a large variety of gene lengths, in contrast to the capsid 
restricted capacity of viruses. Although synthetic vectors are now routinely used in 
laboratories, their very low delivery efficiency remains prohibitive for their use in gene 
delivery (Marvaniya, et al,4; Li, et al,12; Niidome, et al,13; Voulgarakis, et al,30).  
One major approach in nonviral gene therapy is based on cationic polymers. In the 
following pages we will focus on an example of this type of polymer, a modified 
polyamidoamine (PAMAM) dendrimer. 
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2. MICROBIAL RESISTANCE  
Genes for resistance to antibiotics, like the antibiotics themselves, are ancient. 
However, the increasing prevalence of antibiotic-resistant bacterial infections seen in 
clinical practice stems from antibiotic use both within human medicine and veterinary 
medicine. In some countries, antibiotics are sold over the counter without a prescription, 
which also leads to the creation of resistant strains (R. Murray,31). In medicine, the 
major problem of the emergence of resistant bacteria is due to misuse and overuse of 
antibiotics. Pseudomonas aeruginosa is a highly prevalent opportunistic pathogen. One 
of the most worrisome characteristics of P. aeruginosa is its low antibiotic 
susceptibility, which is attributable to a concerted action of multidrug efflux pumps with 
chromosomally encoded antibiotic resistance genes (for example, mexAB-oprM, 
mexXY, etc.) and the low permeability of the bacterial cellular envelopes.  
As resistance towards antibiotics becomes more common, a greater need for 
alternative treatments arises. However, despite a push for new antibiotic therapies there 
has been a continued decline in the number of newly approved drugs. Antibiotic 
resistance therefore poses a significant problem. Novel therapies combining standard 
antibiotics and synthetic vectors are being developed (Calabretta, et al,32; Lopez, et 
al,33; Tang, et al,34; Wang, et al,35; Hong, et al,36; Cheng, et al,37; Feliu, et al,38; 
Tyssen, et al,39; Rasines, et al,40).  
 
 
3. DENDRIMER-BASED VECTORS   
3.1 Cationic Polymers   
Polymers are very versatile molecules that can be tuned to act as gene carriers. 
Variations in polymer molecular weight, 3-D architecture, size, chemical composition, 
number of repeating units, degree of branching, side chain length, density, etc., may be 
used in vector’s design (Majoros,2). Cationic polymers have been used since the last 
three decades as a material for gene delivery (Majoros,2; Tomalia, et al,16). They 
possess high density of positively charged primary amines which can interact with the 
negatively charged phosphate groups of DNA to form condensed structures 
(polyplexes) which enter cells by endocytosis. Several kinds of cationic polymers have 
been reported to mediate efficient gene transfection of different cells lines, such as Poly-
L-lysine (PLL), which was the first cationic polymer based gene delivery vehicle, 
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Polyethylenimine (PEI) and PAMAM dendrimers (Bai, et al,8; Chen, et al,14; Fant, et 
al,28; Hong, et al,36; Cheng, et al,37; Dufes, et al,41; Hadidi, et al,42).  
 
 
 
 
 
 
 
 
 
 
 
3.2 Dendritic architectures  
Since the discovery of dendrimers in the late 70’s, the research interest for developing 
new synthetic routes as well as finding new applications for dendrimers are ever 
increasing (Tomalia, et al,43). Dendrimers are three-dimensional macromolecules that 
can be prepared with a level of control not attainable with most linear polymers, leading 
to nearly monodisperse, globular macromolecules with a high surface area and large 
number of peripheral groups and reproducible formulations (Majoros,2).   
A dendrimer is built up of layers of repeating units around a central core. Each layer 
of monomers builds up one generation, starting with the central branched core molecule 
as generation 0 (G0) and increasing with each successive addition of branching points 
(i.e., G1, G2, etc.). Dendritic macromolecules tend to linearly increase in diameter and 
adopt a more globular shape with increasing dendrimer generation, while the number of 
end-groups increases exponentially with each generation, resulting in a large number of 
terminal units at high generations (Majoros,2; Navarro, et al,44).  
Figure 1.5. Chemical structures of selected cationic polymers (Majoros,2).  
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Dendrimers offer the precise control and predictability of modifications that is 
required for modern drug delivery and targeting. Almost all aspects of the dendrimer 
can be modified through the different parts of the dendrimers to fit different needs, 
including its chemical nature, molecular weight, size, structure, and dimensions. In 
addition, the molecular dimensions of higher generation dendrimers are comparable to 
the dimensions of medium-sized proteins (Marvaniya, et al,4; Tomalia, et al,16).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Chemical structures of PAMAM Dendrimers (G4, G3, G2) and dendrimer generation 
(adapted from (Majoros,2)).  
 
Figure 1.7. Parts of a PAMAM dendrimer (adapted 
from (Wolinsky, et al,6)).  
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3.3 Synthesis and Features   
In the early eighties, the development of dendrimers progressed until Tomalia et al. 
synthesised branched “Starburst” polyamidoamine (PAMAM) molecules and coined the 
name dendrimers, which is derived from the greek words dendron (tree) and meros 
(part). These dendrimers were the first ones to become commercially available.  
The dendrimer can be grown outwards from a central core, a process known as the 
divergent method pioneered by Tomalia and Newkome, or it can be prepared by 
Fréchet's convergent method.  
In the divergent methods, dendrimer grows outwards from a multifunctional core 
molecule. The core molecule reacts with monomer molecules containing one reactive 
and two dormant groups giving the first generation dendrimer. Then the new periphery 
of the molecule is activated for reactions with more monomers. The process is repeated 
for several generations and a dendrimer is built layer after layer (Fig. 1A). The 
divergent approach is successful for the production of large quantities of dendrimers.  
The convergent methods were developed as a response to the weaknesses of the 
divergent synthesis. In the convergent approach, the dendrimer is constructed stepwise, 
starting from the end groups and progressing inwards. When the growing branched 
polymeric arms, called dendrons, are large enough, they are attached to a 
multifunctional core molecule  (Fig. 1B). The convergent growth method has several 
advantages. It is relatively easy to purify the desired product and the occurrence of 
defects in the final structure is minimized.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8. A) The divergent growth method; B) The convergent growth method  
(Marvaniya, et al,4).   
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3.4 Physicochemical Properties   
Because of their molecular architecture, dendrimers show some unique physical and 
chemical properties, which make them particularly interesting for drug and gene 
delivery applications. In contrast with linear polymers, the intrinsic viscosity of 
dendrimer solutions does not increase linearly with mass but shows a maximum at a 
specific generation (Nandy, et al,5). This is likely to be because of the way in which 
dendrimer shape changes with generation (ie, lower generations adopt a more open 
planar-elliptical shape with transition to a more compact spherical shape for higher 
generations). The compact shape also reduces the likelihood of entanglement, which 
affects larger classic polymers. The actual conformation for dendrimers, however, 
depends on the nature of the solvent. The presence of numerous terminal groups 
facilitates multiple simultaneous interactions with solvents, surfaces, or other molecules 
and, as a consequence, dendrimers tend to show high solubility, reactivity, and binding.   
 
 
 
 
 
 
 
 
 
 
 
 
3.5 PAMAM and PAMAM-modified dendrimers  
In recent years, PAMAM dendrimers and modification of their surface functional 
groups with targeting compounds, fluorescent functional groups and drugs have been 
investigated as carriers for gene therapy, magnetic resonance, development of vaccines, 
antivirals, antibacterials and anticancer therapies (Maruyama-Tabata, et al,27; Dufes, et 
al,41; Kim, et al,45). The advantage of PAMAM dendrimers as a drug carrier is that 
they are highly branched macromolecules, small in size with a low polydispersity 
(Wolinsky, et al,6). Ideal PAMAM dendrimers used as a drug delivery system should be 
non-toxic, no-immunogenic and biodegradable.  
Figure 9. Equilibrium snapshot of ssDNA-dendrimer complexes at (a) high, (b) neutral 
and (c) low pH. The dendrimer has been shown in sphere representation in different shades of 
blue and pink, while the DNA is shown in the cartoon representation (Majoros,2; Nandy, et 
al,5).  
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Their synthesis is a divergent process starting from an ethylenediamine core, the 
repetitive steps are a Michael addition of amines to the double bond of methylacrylate 
and the formation of mide bonds between the terminal esters and ethylenediamine 
(Majoros,2).  
This dendrimers are considered a proton-sponge, which contain a large number of 
secondary and tertiary amines, exhibiting pKa values between physiological and 
lysosomal pH. That means that in a physiological environment (pH 7.4), most primary 
amines of the PAMAM dendrimer are protonated, while tertiary amines inside the 
dendrimer are not protonated until the pH drops to 4 (Marvaniya, et al,4; Wolinsky, et 
al,6). Because of this, they have an increase overall ionic interaction with DNA and 
other negatively-charged molecules (such as Adenoviruses) and produce very stable and 
highly soluble DNA complexes (Hadidi, et al,42).  
However, as observed with other cationic macromolecules, including liposomes and 
polymeric micelles, PAMAM dendrimers with positively charged surface groups are 
prone to destabilize cell membranes and cause cell lysis (Wolinsky, et al,6; Qi, et al,29). 
Many functionalization strategies have been employed to mask the terminal amino 
groups and thereby reduce the inherently associated positive charge and resultant 
cytotoxicity. One way to reduce the cytotoxicity of cationic dendrimers involves partial 
surface derivatization with chemically inert functionalities such as polyethylene glycol 
(PEG). This observation can be explained by the reduced overall positive charge on 
these surface-modified dendrimers (Wolinsky, et al,6; Fant, et al,28; Qi, et al,29; 
Hadidi, et al,42; Navarro, et al,44; Huang, et al,46).  
All the studies performed on this work were carried out using a modified PAMAM 
dendrimer. We report the use of a poly(ethylene glycol) methyl ether (mPEG)-G3-
polyamidoamine (PAMAM) dendrimer.  This was in part because PAMAM generations 
0 through 10 (G0–G10) are commercially available featuring a wide number of 
peripheral groups (4 to 4096), end-group functionality (e.g. amine, carboxylic acid, 
hydroxyl) and molecular weights (657 to 935,000 g/mol).   
Here we will show some possible applications different to any described up to the 
moment by using this dendrimeric form. The growth of mesenchymal stem cells and 
bacterias (such as Pseudomonas) were opposite but with potential clinical application 
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4. OBJECTIVES IN THIS PROJECT     
 
The specific objectives to reach will be:  
 
1. Characterize the formation of complexes and stability in cell culture conditions of 
the dendrimeric form.  
 
2. To test the toxicity of the dendrimer through in vitro experiments to be complexed 
on a near future to therapeutic DNA or adenoviruses to suffer of EPR effect and will 
target specifically tumors.    
 
3. To study the growth changes on the MSCs culture conditions when incubated with 
PAMAM-based dendrimeric forms and how they could make an influence on the 
surface markers or pluripotency status of the cell 
 
 
4. To test the potential antimicrobial efficiency of the dendrimer.  
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 PART II: MATERIALS AND METHODS 
  
1. SYNTHESIS OF mPEG2000-G3-PAMAM  
The commercial amine-terminated G3 PAMAM dendrimer with an ethylenediamine 
core (20 wt% in methanol, Sigma-Adlrich, Spain) was vacuum-dried to remove traces 
of methanol. Poly (ethylene glycol) methyl ether (PEG, Mn=2000) was first thoroughly 
dried and then dissolved in tetrahydrofuran (THF) and triethylamine (TEA) (both 
distilled and dried). PEG was firstly activated via a reaction with p-nitrophenyl 
chloroformate chloride, which was slowly added to the mixture and stirred for 24h at 
room temperature (a calcium chloride tube is used to prevent any moisture from getting 
into the reaction vessel). The hydroxyl groups of methylated PEG reacted with the 
reagent and eliminated a molecule of HCl, as shown in Figure 2.1. The salt was filtered 
off and the filtrate was concentrated and then added dropwise to diethyl ether to 
precipitate as activated mPEG p-nitrophenyl chloroformate. The precipitate was 
dissolved in THF again and it was purified by reprecipitation from THF into diethyl 
ether. Alternatively, the purification could be carried out in a Sephadex-LH20 column 
using MeOH as eluent.  
Next, pegylation was performed by linking activated p-nitrophenyl chloroformate 
PEG (4-NPC-PEG) with G3 PAMAM dendrimer. A solution of the dendrimer was 
dissolved in dimethyl sulfoxide and mPEG p-nitrophenyl carbonate was added to the 
solution at 4ºC and then stirred for 72h at room temperature. The reaction mixture was 
evaporated using a rotatory evaporator. The obtained product was dissolved in distilled 
water and filtrated in order to eliminate the low molecular weight reagents. The solid 
product was characterize by 1H MNR and kept protected from moisture and light.  
The synthesis was carried out with the collaboration of Ramón Cervera, from the 
Liquid Crystals and Polymers Group (University of Zaragoza).  
 
 
 
 
 
 
 
Fig 2.1. Diagram showing the 
synthesis of mPEG-G3-PAMAM 
dendrimer (Bai, et al,8).  
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2. STRUCTURAL ANALYSIS OF mPEG2000-G3-PAMAM  
2.1 Material Characterization     
The stoichiometry of mPEG2000-G3-PAMAM was established by 1H NMR. Since 
each PAMAM dendrimer conjugate was not unimolecular, characterization represented 
the average value from its polymeric distribution. Spectra were recorded on a Bruker 
AVANCE 400 spectrometer operating at 400 or 300 MHz and using DMSO and 
d6/D2O as solvents. Chemical shifts are given in ppm relative to TMS, and the solvent 
residual peak was used as internal standard. Ten milligrams of the dendrimer were 
dissolved in DMSO or deuterated solvent to perform the analysis.   
MALDI mass spectra were obtained using 2,5-dihydroxybenzoic acid (DHB) and 
2,4,6-trihydroxyacetophene (THAP) as matrices on a AUTOSPEC Vacuum General. 
Average molecular weights were calculated from the mass range encompassing the 
desired major peak.  
Fourier transform infrared (FTIR) spectra were recorded on a Mattson Genesis II 
FTIR. Samples were scanned between 4,000 and 700 cm-1 at a resolution of 1cm-1.  
 
2.2 Assessment of dendrimer degradation  
mPEG2000-G3-PAMAM was dissolved in DMSO-d6/D2O (10mg/ml) or left solid. 
Some of the aliquots were kept protected from light but others were exposed to light at 
4ºC, room temperature and 37ºC for periods of time ranging from 24-72h. The solid 
samples were dissolved in DMSO-d6/D2O (10mg/ml) right before the analysis.  
The integrity of mPEG2000-G3-PAMAM was established by 1H NMR using the same 
equipment and conditions as previously described (Bruker AVANCE 400).  
 
 
3. DNA-DENDRIMER COMPLEX FORMATION  
3.1 Plasmid DNA Preparation  
The pEGFP plasmid (Addgene, USA) was amplified in chemically modified E.coli 
DH5α (competent bacteria) according to standard procedures and it was purified using a 
NucleoBond Xtra Midi extraction kit (Macherey-Nagel, Germany) according to the 
manufacturer’s instructions.  
Briefly, E.coli competent bacteria (they are more likely to incorporate foreign DNA as 
their cell walls are altered, so that DNA can pass through more easily) were thaw on ice, 
an then a volume of pEGFP was added and everything was incubated on ice for 30 
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minutes. The mixture was heat-shocked by incubating it at 42°C for 30 seconds in a 
thermo-shaker TS-100 (Biosan, Latvia) and then they were placed on ice immediately 
(to reduce damage to the cells). Luria Broth (LB) medium was added to the cells, and 
incubated at 37°C for 1 hour with agitation in a thermo-shaker. Several dilutions of the 
transformation mixture were plated onto separate LB-amp agar plate and grown 
overnight at 37ºC in a bacteriological incubator (Incubat, JPSelecta, Spain). Inoculated 
plates were incubated inverted to prevent the condensation of water from dropping onto 
the agar surface, which can result in the colonies coalescing.    
Colonies were picked and placed in LB-kanamycin (25µg/ml), and then incubated at 
37ºC in a shaking incubator KS 4000i control (IKA, Germany) overnight. The culture 
was transferred to centrifuge tubes and the pellet resuspended in different lysis buffers 
that contain Tris-EDTA, RNase, sodium hydroxide and SDS. These compounds lead to 
the rupture of the cell wall and membrane, and also inhibit nucleases and degrade RNA 
and chromosomal DNA (but not the covalently closed circular plasmid DNA). Plasmid 
DNA was precipitated with 60% isopropanol, washed with 70% ethanol, air-dried and 
finally resuspended in dH2O.  
DNA concentration and purity of pEGFP were determined by using a NanoDrop 
spectrophotometer (Thermo Scientific, Spain). The intactness and identity of the 
plasmid were confirmed by agarose gel electrophoresis. For linearization, the plasmid 
was digested with PStI (New England Biolabs, UK).   
To prepare LB-broth, the premix LB powder was dissolved (1% bacto-tryptone, 0.5% 
yeast extract, 1% NaCl (w/v)) (Scharlau, Scharlab, Spain) in dH2O while heating and 
then the mixture was autoclaved (20 mins, 121ºC, 2atm). The medium was kept at 4ºC. 
To make the LB-agar plates, the premix LB powder was dissolved (1% bacto-tryptone, 
0.5% yeast extract, 1% NaCl, 1.5% agar (w/v)) (Scharlau, Scharlab, Spain) in dH2O 
while heating and then autoclave the bottle (20 mins, 121ºC, 2atm). Agar was cooled to 
~55ºC and additives added when necessary, such as ampicillin (100 µg/ml) or 
kanamycin (25 µg/ml). A thin layer of LB Agar (~10ml) was poured into each plate and 
cooled until it was solid. Plates were flipped so as to avoid condensation on the agar and 
stored at 4ºC until usage.   
All the procedures were carried out at the flame (Bunsen), and all the materials (30 
mins, 121ºC, 2atm) and solutions (20 mins, 121ºC, 2atm) were autoclaved or filtered 
(0.2 µm syringe filter) and sprayed with 70% ethanol to ensure sterile conditions so as 
to prevent contamination.   
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3.2 Gel Retardation Assay   
This assay is also known as electrophoretic mobility assay and it is used to study the 
formation of DNA-particle complexes. The technique of electrophoresis is based on the 
fact that DNA is negatively charged at neutral pH due to its phosphate backbone. For 
this reason, when an electrical potential is placed on the DNA it will move towards the 
positive pole. The rate at which the DNA will move is slowed by making the DNA 
move through an agarose gel. The agarose forms a porous lattice and the DNA slips 
through the holes.  
In summary, the basis of the assay is that, as the size of the DNA-particle complexes 
is larger than DNA alone, they should migrate more slowly than the free DNA 
fragments.    
The gel was done by mixing the agarose (Lonza, Spain) with 1X TAE (Tris-acetate-
EDTA) buffer and heating until the agarose was dissolved. The agarose was cooled and 
ethidium bromide (a DNA intercalating agent used as a fluorescent dye) (Fermentas, 
Thermo Fisher Scientific, Spain) was added. The mixture was poured into a gel 
electrophoresis tray with a comb -to make the wells- and let dry for 45 minutes.  
mPEG2000-G3-PAMAM and pDNA were diluted in dH2O and Vector/pDNA 
complexes were prepared at various weight ratios ranging from 0.1:1 to 400:1 and 
incubated for 30 minutes at room temperature. The complexes were mixed with 
appropriate amounts of 6X loading buffer (which contains a dye to assess how fast the 
gel is running and a reagent to render the samples denser than the running buffer) 
(Takara, UK) and then electrophoresed on a 0.5% (w/v) agarose gel containing ethidium 
bromide (0.5 µg/ml) for 45 minutes at 100V. All the gel electrophoresis equipment used 
was supplied from Biorad (Spain). The location of pDNA in the gel was analyzed on a 
G:Box UV transilluminator (Syngene, UK).  
 
 
4. EVALUATION OF BACTERIAL GROWTH          
4.1 Bacterial Preparations    
The bacteria used in the analysis were Escherichia coli and E.coli-EGFP (Gram-
positive, G+), Pseudomonas aeruginosa (Gram-negative, G-), Enterobacter 
aerogenes(Guo Qing-Song, et al,47), Salmonella typhimurium (Guo Qing-Song, et 
al,47) and Staphylococus.aureus (G+) (kindly donated by the University Francisco de 
Vitoria, Madrid). Gram-positive bacteria retain the color of the crystal violet stain in the 
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Gram stain because their cell wall is composed of a thick layer of peptidologlycan; 
Gram-negative bacteria lose the crystal violet stain because their layer of 
peptidologlycan is very thin. All the microorganisms were grown at 37ºC and 
maintained in LB-agar plates at 4ºC; E.coli-EGFP was maintained in LB-kanamycin. 
Inoculated plates are incubated inverted to prevent the condensation of water from 
dropping onto the agar surface.  
To freeze the bacteria, one colony from each plate was inoculated in LB-broth and 
grown at 37ºC O/N while shaking. Each bacterial suspension was diluted with sterile 
glycerol solution to a final 15%v/v glycerol concentration. The samples were kept in ice 
during the process and at the end quickly transferred to a -80°C freezer for long-term 
storage. For thawing, bacteria were left on ice for 30 minutes and the suspension 
directly plated. Bacteria were incubated O/N at 37ºC.  
All the procedures were carried out at the flame (Bunsen), and all the materials (30 
mins, 121ºC, 2atm) and solutions (20 mins, 121ºC, 2atm) were autoclaved or filtered 
(0.2 µm syringe filter) and sprayed with 70% ethanol to ensure sterile conditions so as 
to prevent contamination.  
 
4.2 Bacterial Assays   
4.2.1. LB plate assay  
Ampicillin (Sigma, Spain), kanamycin (Invitrogen by Life Technologies, Thermo 
Fisher Scientific, Spain) and mPEG2000-G3-PAMAM were added to LB-agar plates at 
different concentrations ranging from 0.5-500 µg/ml and let air-dry. Aliquots of each 
culture were left O/N on LB in agitation at 140 rpm and were then plated. Both 
antibiotics and dendrimer solutions were previously diluted in dH2O and filtered with a 
0.2 µm syringe filter besides the flame. Plates were incubated at 37°C to allow colony 
formation and observed after 24h.    
 
4.2.2. LB broth assay  
Ampicillin, kanamycin and mPEG2000-G3-PAMAM (diluted in dH2O and filtered with 
a 0.2 µm syringe filter) were added to LB-broth at 50, 100 and 500 µg/ml and then a 
colony from each bacteria strain was resuspended in each broth. Bacteria suspensions 
were checked for turbidity after 24h incubation at 37ºC while shaking at 140 rpm and 
the positive suspensions with the higher antibiotic or dendrimer concentration were 
plated in LB-agar and incubated overnight.   
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4.2.3. LB microplate assay  
The minimum inhibitory concentration (MIC) of the PAMAM derivatives, that is, the 
lowest concentration of the compounds that inhibits the visible growth of P.aeruginosa 
and S.aureus after 18-24 h of incubation, was determined using a broth microdilution 
technique. A pre-inocule of P. aeruginosa and S.aureus were grown O/N in agitation in 
LB-broth. Serial dilutions of the bacterial suspensions were prepared in a 24-well plate 
(MW24) and absorbance was measured to adjust the bacteria concentration to 2x105 
CFU/ml (Abs~0.20 at 630 nm) (stock solution). Dilutions of mPEG2000-G3-PAMAM 
were prepared in dH2O (50-4000 µg/ml).  
The stock bacterial solutions were distributed into a 96-well sterile plate (MW96) and 
each of the prepared dendrimer solutions was added to the wells. Control wells were 
composed of bacterial solutions without dendrimers (positive controls) and LB medium 
without bacteria but with dendrimer (negative controls). To reduce evaporation during 
incubation (which is critical to the assay), each of the empty outer wells of the 
microtiter plate was filled with sterile water to increase the water vapor pressure in the 
incubator. The microtiter plates were incubated at 37 °C and 140 rpm O/N. At the end 
of the incubation, the pellets formed were resuspended prior to scanning the optical 
densities using a Synergy HT (BioTek, USA) at 630 nm, which is proportional to the 
number of bacteria in suspension.  
 
 
5. EVALUATION OF CELL GROWTH     
5.1 Culture of Cell Lines   
Human Neuronal Gliobastoma U251MG cells (Cancer Research UK, Cell Lines 
Services) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 
4.5 g/l D-Glucose, 4 mM L-Glutamine and 1.0 mM sodium pyruvate (Gibco, Invitrogen 
by Life Technologies, Thermo Fisher Scientific, Spain). Also, 10% heat-inactivated 
fetal bovine serum (FBS), 1% penicillin/streptomycin (Lonza) and 1% amphotericin B 
(Lonza) were added to complement the media. Cells were maintained at 37ºC in 
normoxic conditions (21% O2; 5% CO2) in an Excella ECO-170 CO2 incubator 
(New Brunswick Scientific, UK).   
When subculturing, media was removed and cells were washed with DPBS (Gibco, 
Invitrogen by Life Technologies, Thermo Fisher Scientific, Spain). Then, 1% trypsin 
solution (Trypsin-Versene 10X, Lonza) was added and cells were incubated at 37ºC for 
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5 minutes, allowing trypsin to break down the proteins which enable the cells to adhere 
to the vessel. Trypsin action was stopped by adding fresh cell culture media and a part 
of the cells was resuspended and dispensed into a new flask or plate. Cells were 
passaged every 4-5 days (80-90% confluence).   
Murine MSCs (bone marrow of C57BL⁄6 mouse at ≤ 8 weeks after gestation, Gibco, 
Invitrogen by Life Technologies, Thermo Fisher Scientific, Spain by Life Technologies, 
Spain) were cultured in Dulbecco’s modified Eagle’s medium (DMEM-LG) containing 
1 g/l glucose, 2 mM L-glutamine and 1.0 mM sodium pyruvate (Gibco, Invitrogen by 
Life Technologies, Thermo Fisher Scientific, Spain). Also, 10% heat-inactivated fetal 
bovine serum (FBS), 1% penicillin/streptomycin and 1% amphotericin B were added to 
complement the media.   
Alternatively, mMSCs were cultured in MesenCul MSC Basal Medium (Mouse), 
adding 10% MesenCult Mesenchymal Stem Cell Stimulatory Supplements (Mouse) 
(StemCell, Miltenyi Biotec, Spain), 1% penicillin/streptomycin and 1% amphotericin B.    
In both cases, mMSCs were maintained at 37ºC under hypoxic conditions (1% 
Oxygen and 5% CO2) in a Forma Series II Water jacketed CO2 Incubator, HEPA class 
100 (Thermo Fisher Scientific, Spain).   
For subculturing, the same procedure as previously described for U251MG cells was 
followed, but using 2.5% trypsin (Trypsin-Versene 10X, Lonza, Spain) (as in this case 
cells showed a higher adherence). Cells were passaged every 6-7 days when using 
DMEM-LG and every 3-4 days when using MesenCult (in both cases, when cells 
reached 80-90% confluence).    
For freezing, cells were first trypsinize by using the same procedure as for passaging 
them; then the pellet was resuspended with freezing media (80% FBS, sterile 20% 
DMSO) and the cryovial (Simport, USA) was left at -80°C for a minimum of 24h; then 
the vial was transferred to the liquid N2 tank for indefinite storage.   
When thawing, the vial was removed from the liquid N2 tank and it was held it in the 
37°C water bath until the freezing media was thawed. Gently pour cells into a falcon 
tube with PBS, centrifuge and resuspend in media. Media needs to be changed the next 
day to prevent cell damage with possible remaining DMSO.   
All the cultures were tested for mycoplasma and all the cell culture plastic labware 
was supplied by Nunc (Thermo Fisher Scientific, Spain).  
A vertical laminar flow hood Safemate 1.2 (BioAir, Italy) was used for all the 
culturing procedures. The tray was swab with 70% ethanol before and after each use 
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and UV was irradiate for 10 minutes. Full protective clothing and nitrile gloves must be 
worn at all times when using the hood and the incubators.  
Cells were observed under an AE31 Research Grade Inverted Microscope (Motic, 
Spain) and manually counted using a Neubauer hemocytometer chamber (Blaubrand, 
Germany).  
 
5.2 Viability Assays   
5.2.1. Crystal Violet method  
Crystal violet (CV) is a triphenylmethane dye (4-[(4-dimethylaminophenyl)-phenyl-
methyl]-N,N-dimethyl-aniline) that stains DNA. CV is a simple assay that is useful for 
obtaining quantitative information about the relative density of cells adhering to multi-
well cluster dishes. Upon solubilization, the amount of dye taken-up by the 
monolayer and the intensity of the color produced are proportional to cell number.  
U251MG and mMSCs cells were seeded at a density of 2x103 cells/well in a MW96, 
or alternatively at 4x104 cells/well in a MW24. A stock solution of 50mg/ml was made 
on the moment by diluting the dendrimer in dH2O. Then, the solution was filtered with a 
0.2µm syringe filter (25mm diameter, Nalgene, Labclinics, Spain) in the laminar flow 
hood and kept protected from light at 4ºC.   
Upon 24h incubation and without removing the media, fresh media was added to the 
control wells and mPEG2000-G3-PAMAM diluted in media at different concentrations 
(0.5, 1 and 5 mg/ml) was added to the rest of the wells (in triplicate). Media was 
removed after 24, 48 and 72h of incubation with the dendrimer and cells were fixed 
with 1% Glutaraldehyde for 10 mins; then, PBS was added and the plate was kept in the 
incubator until the day of the analysis. Then, PBS was removed and 0.1% crystal violet 
(dissolved in ethanol) (Roth, Spain) was added for 30 mins at room temperature. After 
the staining, the dye was removed washing with tap water and the plate air-dried for a 
couple of days at room temperature. 10% acetic acid was added to the wells to extract 
the dye from the cells, transferred to a new MW96 and absorbance read on a Synergy 
HT (BioTek, USA) plate reader at 590nm. Citotoxicity was expressed as relative 
viability of cells (% of the control cells incubated with medium only). All the 
experiments were repeated at least three times.  
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5.2.2. Alamar Blue method  
Resazurin (7-hydroxy-10-oxido-phenoxazin-10-ium-3-one) is a redox dye that is 
commercially available as Alamar Blue, which exhibits both colorimetric and 
fluorometric change that relates to cellular metabolic activity. The assay is based on the 
ability of viable, metabolically active cells to reduce resazurin to resorufin and dihydro-
resorufin. This conversion occurs intracellularly, where the oxidized form of the 
resazurin enters the cytosol and is converted to the reduced form by mitochondrial 
enzyme activity by accepting electrons from NADPH, FADH, FMNH, NADH as well 
as from numerous cytochromes. The reduction related to growth causes the resazurin to 
be converted from the oxidized (or non-fluorescent) blue form to the reduced 
(fluorescent) red form. Since Resazurin is not-toxic to cells and is stable in culture 
media, continuous measurement of cell proliferation in vitro can be achieved. Toxic 
compounds that impair cell viability and proliferation also affect the capacity to 
reduce resazurin, and the rate of dye reduction is directly proportional to the 
number of viable cells present.  
U251MG and mMSCs cells were seeded at a density of 1-3x103 cells/well in a MW96. 
Upon 24h incubation, media was removed and fresh media was added to the control 
wells and mPEG2000-G3-PAMAM diluted in media at different concentrations (0.5, 1 
and 5 mg/ml) was added to the rest of the wells (in triplicate). The dendrimer stock 
solution at 50mg/ml in dH2O was prepared as previously described.  
Media was removed after 24, 48 and 72h of incubation with the dendrimer and fresh 
media was added to all the wells (control and sample wells); then a 10% of the media 
volume of Alamar Blue solution (Invitrogen by Life Technologies, Thermo Fisher 
Scientific, Spain) was added. The reading of the plates was done on a daily basis to 
prevent the cells from contaminating, so they were seeded in different plates, and each 
plate was discarded after measuring the fluorescence. After 3h incubation at 37ºC, 
fluorescence was read at 530/590 (excitation/emission) on a Synergy HT (BioTek, 
USA) plate reader. Citotoxicity was expressed as relative viability of cells (% compared 
to the control cells incubated only with medium).  
To set up the best conditions, different combinations were assayed (seeding 
concentration, culturing media, incubation time with assay reagent, etc), but in all cases 
the experiments were repeated at least three times.  
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5.2.3. MTT method  
The MTT assay is a sensitive, quantitative and reliable colorimetric assay that 
measure viability, proliferation and activation of cells. The assay is based on the 
capacity of the cellular mitochondrial dehydrogenase enzyme in living cells to reduce 
the yellow water-soluble substrate 3-(4,5-dimethylthiazol- 2yl)-2,5-diphenyl tetrazolium 
bromide (MTT) into a dark blue/purple formazan product which is insoluble in water. 
The amount of formazan produced is directly proportional to the cell number. The MTT 
assay has greater applicability in the detection of cells which are not dividing but are 
still metabolically active. It can, therefore be used to measure the cell proliferation rate 
and conversely, when metabolic events lead to apoptosis or necrosis, the reduction in 
cell viability. Unfortunately, during conduct of the test, cells die making it impossible to 
conduct follow-up cell culture assessments.  
mMSCs cells were seeded at a density of 1-3x103 cells/well in a MW96 and allowed 
to attach overnight. Media was removed and fresh media was added to the control wells 
and mPEG2000-G3-PAMAM was diluted in media at different concentrations (0.5, 1 and 
5 mg/ml) was added to the rest of the wells (five replicates). The stock solution of 
dendrimer at 50mg/ml in dH2O was prepared as previously described. A stock solution 
of 5mg/ml MTT (Serva electrophoresis, Labclinics, Spain) in PBS (pH 7.4) was made 
and filtered with 0.2µm syringe filter; aliquots were kept protected from light at -20ºC.  
Media was removed after 24, 48 and 72h of incubation with the dendrimer and fresh 
media was added to all the wells (control and sample wells); then MTT solution was 
added to a final concentration of 0.5mg/ml. As in the case of Alamar Blue, the reading 
of the plates was done on a daily basis to prevent the cells from contaminating, so they 
were seeded in different plates, and each plate was discarded after measuring the 
fluorescence. After 4h incubation at 37ºC, MTT solution was removed and 
dimethylsulfoxide (DMSO) was added to dissolve the insoluble formazan crystals. 
Finally, absorbance was read at 570nm on a Synergy HT (BioTek, USA) plate reader. 
The viability of mMSCs cells exposed to the dendrimers was expressed as a percentage 
of the viability of cells grown in the absence of the dendrimers. 
Different conditions were assayed (seeding concentration, culturing media, incubation 
time with assay reagent …), but in all cases the experiments were repeated at least three 
times.  
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5.2.4. Interference Tests  
To eliminate possible interferences between the dendrimer assay readings, media 
(complete DMEM) alone or with different concentrations of sterile mPEG2000-G3-
PAMAM were added to a MW96 in triplicate and incubated at 37ºC for 24h. After the 
incubation period, wells were washed with PBS and then the assay reagent was added, 
or alternatively the assay reagent was directly added without washing. The assay 
reagents were crystal violet, alamar blue and MTT, and the procedures followed were 
the ones described above.  
In a different assay, cells were seeded at 1-3x103 cells/well in a MW96, incubated for 
24h at 37ºC and treated with the same concentrations of mPEG2000-G3-PAMAM. The 
procedures described previously for crystal violet, alamar blue and MTT were followed, 
but without the addition of the assay reagents.    
 
5.2.5. Trypan Blue method   
Trypan blue is a diazo dye used to selectively color dead cells in blue. Since cells are 
very selective in the compounds that pass through the membrane, in a viable cell trypan 
blue is not absorbed; however, it goes through the membrane in dead cells. Hence, dead 
cells are shown as a distinctive blue color under a microscope. However, trypan blue 
staining cannot be used to distinguish between the healthy cells and the cells that are 
alive but losing cell functions.  
To reassure, mMSCs were seeded at 1-3x103 cells/well in a MW96 and incubated for 
24 h at 37ºC. Cells were washed with DPBS and trypsinized. 0.4% trypan blue in PBS 
was added to the cell suspension in a 1:1 to 1:5 ratios (depending on the cell 
concentration) and incubated at room temperature for 3-5 min. Viable and dead cells 
were manually counted using a Neubauer hemocytometer chamber. Viability values of 
treated cells were expressed as a percentage of that from corresponding control cells.  
 
 
 
 
 
 
 
 
 CV AB MTT TB 
Direct cell counting  
technique 
x     x 
Metabolic active cells   x x   
Cell proliferation rate   x x   
Living-cell exclusion  
(vital stain) 
x     x 
Non-toxic to cells   x     
Figure 2.2. Summary of the principal characteristics of the different 
viability methods.    
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5.3 Gelatin Assay    
Sterile mPEG2000-G3-PAMAM (previously filtered) was diluted in PBS-0.1% gelatin 
solution (Type B, 2% in H2O, Sigma, Spain) to different concentrations (0.5, 1 and 5 
mg/ml), added to the wells of a MW96 plate and incubated 1h at room temperature. 
Then, surplus dendrimer-PBS-gelatin solution was removed and a fine layer of the 
gelatin-dendrimer complex remained at the bottom of the wells.   
U251MG and mMSCs cells were seeded over the gelatin at a density of 
3x103cells/well in a MW96. Media was removed after 24, 48, 72 and 96h of incubation 
with the dendrimer and fresh media was added to all the wells (control and sample 
wells); then a 10% of the media volume of Alamar Blue solution (Invitrogen by Life 
Technologies, Thermo Fisher Scientific, Spain) was added. From this point, the 
procedure was carried out the same as the Alamar Blue protocol. Citotoxicity was 
expressed as relative viability of cells (% of control cells incubated with medium only).  
 
5.4 Evaluation of Cellular Alterations     
5.4.6. Analysis of Cell Cycle and Immunophenotyping   
Flow cytometry is a technology that allows a single cell to be measured for a variety 
of characteristics, determined by looking at how they flow in liquid and measuring 
visible and fluorescent light emissions, allowing cell sorting based on physical, 
biochemical and antigenic traits.   
Analysis of a population of cells’ replication state can be achieved by fluorescence 
labeling of the nuclei of cells in suspension and then analyzing the fluorescence 
properties of each cell in the population. This approach reveals distribution of cells in 
three major phases of the cycle (G1 vs S vs G2/M) and makes it possible to detect 
apoptotic cells with fractional DNA content.  
For the cell cycle analysis, mMSCs cells were seeded into P60 plates at 
1x106cells/plate and incubated at 37ºC for 24h.  Then, cells were washed with DPBS 
and fresh media was added to the control plate and a dilution of dendrimer (1mg/ml) 
was added to the sample plate. Cells were incubated another 72 hours. This 
concentration of dendrimer was chosen based on the results obtained in the citotoxicity 
assays (see Results section). After the incubation, cells were washed with DPBS, 
trypsinized and centrifuged. The pellet was resuspended in media, 1x106 cells were 
counted and separated into a new tube and centrifuged again. The pellet was washed by 
resuspending cells in DPBS and centrifuging. Finally, cells were fixed (for the 
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permeabilisation of the cell plasma membranes) by resuspending them in DPBS and 
then ice-cold 70% ethanol was slowly added to the side of the tube. Cells can be kept at 
-20°C for a maximum of a week. At the day of analysis, the cells were washed from 
ethanol, stained with 5 µg/ml propidium iodide (PI, Becton Dickinson, Spain) at the 
presence of RNase A (Invitrogen by Life Technologies, Thermo Fisher Scientific, 
Spain) for 30 min at 37°C.    
 
Antibodies are powerful tools for studying cell surface protein expression signatures. 
For the immunophenotyping analysis, a fluorescent dye is attached to antibodies and 
these cells can then be subjected to flow cytometry and the amount of the receptor on 
their surface detected as a level of fluorescence. Antibodies used for these experiments 
were anti-CD73 (Phycoerythrin (PE)-conjugated), anti-CD105 (FITC-conjugated) as 
positive controls and anti-CD34 (PE-conjugated) (Becton Dickinson, Spain) as negative 
control. mMSCs cells were seeded into P100 plates at 2x106cells/well and incubated at 
37ºC for 24h.  Then, cells were washed with DPBS and fresh media was added to the 
control plate and a dilution of dendrimer (1mg/ml) was added to the sample plate. Cells 
were incubated for 72 hours. After the incubation, cells were trypsinized. 2x106 cells 
were separated into a new tube, washed with DPBS and finally resuspended in PBS-
EDTA. Cell suspensions were separated in different tubes and tested separately for the 
three markers by staining with 5 µg/ml of each antibody.   
The cycle analysis and immunofluorometric analysis were performed using 
FACSAria (Becton Dickinson, Spain). Data were collected at the wavelength of 580 nm 
for PI and PE and 520 nm for FITC.   
 
5.4.7. mMSCs Adipogenic Differentiation    
Mesenchymal stem cells are multipotent in nature and have the unique ability to 
differentiate into various cell types. Therefore, to confirm the identity of cells as MSCs, 
their adipogenic differentiation potential was evaluated.  
mMSCs cells were seeded into MW12 at 1.2x105 cells/well (3x104 cells/cm2) with 
MesenCult Basal Medium (Mouse) and incubated at 37ºC for 24h. Then, cells were 
washed with DPBS and fresh media (Basal MesenCult) was added to the positive 
control wells (+ctr) (Sample A, Figure 2.2) and a dilution of dendrimer (1mg/ml in 
MesenCult Basal Medium) was added to the sample wells (+D) (Sample C, Figure 2.2). 
Cells were incubated for 72 hours. This concentration of dendrimer was chosen based 
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on the results obtained in the citotoxicity assays (see Results section). Adipogenesis was 
induced by culturing confluent mMSCs (+ctr and +D wells) in Complete MesenCult 
Adipogenic Medium (Mouse) (StemCell, Miltenyi Biotec, Spain). This media was 
prepared by diluting Adipogenic Stimulatory Supplement (Mouse) (StemCell, Miltenyi 
Biotec, Spain) 1/5 with MesenCult MSC Basal Medium (Mouse); 1% 
peniciline/streptomycine was added. Negative control cells (-) were maintained in Basal 
MesenCult Medium. Cells were checked every day and media was changed every 2-3 
days.    
Alternatively, cells were seeded into MW24 at 1.5x105 cells/well; after 24h of 
incubation, they were washed with DPBS and adipogenesis was induced by adding 
Complete MesenCult Adipogenic Medium (Mouse) with a dilution of the dendrimer 
(1mg/ml in MesenCult Adipogenic Medium) to the sample wells (+D) (Sample D, 
Figure 2.2). Cells were incubated for 24-48 hours. The positive control wells (+ctr) 
(Sample B, Figure 2.2) were incubated 72h in Basal Medium previous to differentiation. 
After the incubation period, the differentiation process followed as previously explained 
(cells were checked every day and media was changed every 2-3 days).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 
A 
Seeding@ and 24h Incubation 
Sample 
B 
Sample 
C 
Sample 
D 
MesenCult 
Basal 
Medium 
MesenCult 
Basal 
Medium; 
72h 
Incubation 
MesenCult 
Basal 
Medium + 
1 mg/ml 
Dendrimer; 
72h 
Incubation 
MesenCult 
Adipogenic 
Medium + 
1 mg/ml 
Dendrimer; 
24-48h 
Incubation 
Change 
MesenCult 
Adipogenic 
Medium 
every 2-3 
days  
Change 
MesenCult 
Adipogenic 
Medium 
every 2-3 
days (no 
dendrimer 
Change 
MesenCult 
Adipogenic 
Medium 
every 2-3 
days (no 
dendrimer) 
Fig 2.3. Diagram showing the strategy followed for the mMSCs differentiation.   
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In both cases, adipogenic differentiation was confirmed after 14 days by Oil-Red 
staining, which stains lipid droplets within the adipocytes. Oil-Red was prepared by 
mixing Oil-Red powder (Sigma, Spain) with 99% isopropanol (stock solution, one year 
stability). Then, 3 parts of the stock were mixed with 2 parts of dH2O; the mixture was 
left to settle 10 minutes and slowly filter using a funnel and filter paper (stable only for 
2 hours). Cells were observed under an AE31 Research Grade Inverted Microscope 
(Motic) and pictures were taken with a Moticam 5000 cooled Digital Camera.     
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 PART III: RESULTS AND DISCUSSION 
 
1. STRUCTURAL ANALYSIS OF mPEG2000-G3-PAMAM 
The integrity of mPEG2000-G3-PAMAM was tested right after being synthesized (1H 
MNR carried out by R. Cervera). After several weeks the integrity of the dendrimer was 
checked.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Emergence of peaks at 1705cm-1 and 1655cm-1 shows the change in length of –C=O 
(stretching) due to the binding between the carboxyl of mPEG and the amide of 
PAMAM.  
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Figure 3.1. (a) General structure of mPEG-G3-PAMAM and (b)FTIR 
spectrum of mPEG2000-G3-PAMAM dendrimer. The red arrows points at the 
peaks related to a change in length of –C=O. Approximate peaks at 3300cm-1, 
2800 cm-1, 1450 cm-1, 1300 cm-1 and 1100 cm-1 correspond to H-O, C-H, N-H 
(amide II), C-O and C-O-C, respectively.  
a 
b
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As happens in higher dendrimer generation (in this case a lower generation but 
completely covered with long PEG chains), the spectral lines became weak and, as a 
result, we did not obtain a line structure, but a general molecular weight distribution can 
be observed (Fig.3.2). From that spectrum we calculate a theoretical mass of ~ 70000 
Da.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. MALDI-LP 
spectrum of mPEG2000-G3-
PAMAM using DHB as a 
matrix. The red arrow 
points at the calculated 
mass.  
Figure 3.3. 1H NMR spectrum of mPEG2000-G3-PAMAM in DMSO-d6. Red 
arrows point to CH2-PEG, CH3-PEG and DMSO (from left to right); red box 
locates PAMAM-dendrimer-CH2. 
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The results suggested that a mPEG-G3-PAMAM dendrimer complex was formed. All 
the data presented here agrees with previous published results (Kim, et al,48). Finally, 
the integrity of mPEG2000-G3-PAMAM was established by 1H NMR after 18 weeks up 
to 8 months of keeping it in darkness and room temperature. The dendrimer was further 
dissolved in deuterated water and kept protected from light, exposed to light at 4ºC, 
room temperature and 37ºC for periods 72h. Any of the spectra show differences 
compared to the one obtained before (data not shown) concluding that the dendrimer is 
stable at room temperature for long periods of time.  
 
 
2. DNA-DENDRIMER COMPLEX FORMATION 
Currently the practical use of unmodified PAMAM dendrimers has been questioned 
by reports that show relatively high citotoxicity as a result of their high surface charge 
density. Pegylation increases bioavailability of polymer-DNA complex by enhancing 
solubility and increasing the circulation time in the bloodstream; also facilitates 
dissociation of DNA inside the cell (Fant, et al,28).   
Before trying the transfection efficiency of the dendrimer, the amount of plasmid 
DNA that binds the dendrimer is optimized so neither vector nor therapeutic agent is 
wasted.  
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Figure 3.4. Gel Retardation Assay. Ratio 
Plasmid:Dendrimer (increasing amounts of 
plasmid). Lane 1: DNA marker (with known 
bands for estimating the molecular weight of the 
sample bands). Lane 2: negative control with 
dendrimer alone. Lanes 3-9: mixtures of pEGFP 
(concentrations of pEGFP ranging from 0.125-5 
µg) and dendrimer (50 µg). There is no retention 
of Dendrimer-Plasmid complexes in the wells 
(red box). The intensity of the bands related to 
pEGFP increases with increasing plasmid 
concentration (yellow circle).  
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When incubation of the dendrimer with the plasmid DNA, if the ratio is optimal, the 
vector incorporates all the plasmid and the complex formed is retained in the well. 
When the ratio dendrimer:plasmid is higher than the optimal one, extra-not bound 
plasmid runs along the gel. 
The gel retardation assay demonstrated that DNA would not package mPEG2000-G3-
PAMAM dendrimer at D/P ratios up to 400 (Fig. 1). Because it is completely covered 
with mPEG, G3-PAMAM has no external positive charge to bind the plasmid DNA 
(negatively charged) and then it will not be useful for plasmid transfections into the 
cells. 
 
 
3. EVALUATION OF BACTERIAL GROWTH  
We have evaluated the antibacterial activity of mPEG2000-G3-PAMAM against E.coli 
and E.coli-EGFP (Gram-positive, G+), P. aeruginosa (Gram-negative, G-), E. 
aerogenes(Guo Qing-Song, et al,47), S. typhimurium (Guo Qing-Song, et al,47) and S. 
aureus (G+). The cytoplasmatic cell membrane is the main target for many antibacterial 
agents, and PAMAM dendrimers have shown great potential interacting and disrupting 
them (Cheng, et al,37).   
In a first attempt, bacteria were incubated in plates containing LB agar with a dilution 
of the dendrimer at a specific concentration. In order to compare the activity of the 
dendrimer with effective antibiotics commonly used in the lab, similar concentrations 
were tested (from 0.5-100 µg/ml). As it is shown in Figure 3.5, grow inhibition is 
observed in Ampicilin and Kanamycin plates (used as positive controls), but no effect 
can be observed for any of the bacteria with the dendrimer (plates with antibiotics and 
dendrimer at lower concentrations are not shown).   
In a second attempt, bacteria were incubated with the dendrimer in solution, so as to 
favor interactions between both. Again, all the bacteria were found to be resistant to the 
dendrimer at concentrations of 100-500 µg/ml (Fig. 3.6) (lower dendrimer 
concentrations are not shown).  
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Eventually, a more accurate and reproducible assay was used to asses the activity of 
the dendrimer. In this case, instead of incubating the dendrimer with an unknown 
number of microorganisms, we adjusted the number of bacteria to a certain value of 
cfu/ml prior to incubation with mPEG2000-G3PAMAM. Then, the optical density at 635 
nm was measured, which is proportional to the number of bacteria. In this case we only 
used P. aeruginosa and S. aureus, since both are common pathogens in ocular and 
vaginal infections and have been previously tested with PAMAM-derivates successfully 
(Lopez, et al,33).   
 
 
Figure 3.6. Antimicrobial activity of mPEG2000-G3-PAMAM using a broth 
assay. All the bacteria shown here were incubated with 500 µg/ml. LB alone was 
used as the negative control (no turbidity). The increased turbidity is a sign of 
bacterial growth.  
Figure 3.5. Antimicrobial activity using a plate assay using (a) ampicilin (100 µg/ml), (b) 
kanamycin (25 µg/ml) and (c) mPEG2000-G3-PAMAM (100 µg/ml).  
a  b  c  
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As expected, mPEG2000-G3-PAMAM is more efficient in inhibiting the growth of 
P.aeruginosa (Gram-) (concentrations of 100 µg/ml and above) compared to S.aureus 
(Gram+). This can be explained taking into account that the antibacterial action of the 
dendrimers involves disruption of the cytoplasmic membrane of the bacteria, and in the 
case of Gram- bacteria, the top of the plasma membrane is covered by negatively-
charged proteins that facilitate membrane permeation and hence killing of the bacteria. 
We will check in the near future another 2 Gram – bacterias, E. aerogenes (Guo Qing-
Song, et al,47) and S. typhimurium (Guo Qing-Song, et al,47) to test if is a general 
effect in all the Gram - bacterias. 
In the initial assays the bacteria appear to be resistant to the dendrimer at 
concentrations up to 500 µg/ml (Fig. 3.7). In that case we looked at the turbidity to 
determine the result, and in this case, although we measure the OD to obtain more 
specific data, we could also see growth of the bacteria in all the wells, meaning that the 
bacteriostatic effects could be identical in both assays but we did not have enough 
resolution.  
It is also possible that the character of the PEG chains to some extent enhances the 
permeation through the cell membrane. Moreover, the fact that the dendrimer retains 
antibacterial activity at high concentrations (4 mg/ml) could be an effect of the 
detachment of some of the PEG chains from the PAMAM and the dendrimer. Higher 
Figure 3.7. Antimicrobial activity of mPEG2000-G3-PAMAM using a modified 
broth microdilution assay. Gram+ bacteria (blue) and Gram- (pink).  
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concentrations of dendrimer could be tested, but they would be substantially higher than 
those of common antibiotics, and in general terms, more expensive, and then some of 
the advantages would be lost.  
Although PAMAM dendrimers strongly bind to bacteria and third generation has 
proved to be more effective because they easily penetrate towards the bacterial 
membrane (Lopez, et al,33), we can conclude that complete PEGylation deactivates the 
dendrimer against bacteria but our dendrimer still retains some of the antibacterial effect 
against Gram - bacterias.  
 
 
4. EVALUATION OF CELLULAR GROWTH AND ALTERATIONS  
The citotoxicity of PAMAM dendrimers in mammalian cells lines due to the nature of 
the surface charge has been noted. Before using this type of vectors in any in vivo 
application, a citotoxicity profile must be done in vitro.  
In our study, the citotoxicity of mPEG2000-G3-PAMAM dendrimer was evaluated 
using four commonly used methods: Crystal Violet (CV), Alamar Blue (AB), MTT and 
Trypan Blue (TB). At least, two different cell types must be tested, our cells of interest 
(MSCs) and a tumoral cell line (U251MG).  
 
An interesting phenomenon was observed when measuring the cell viability of both 
U251MG (Fig. 3.8a) and mMSCs (Fig. 3.8b) cells after incubation with increasing 
concentrations of the dendrimer at different times (Hoskins, et al,49). The presence of 
the dendrimer resulted in greater absorption readings compared to the control. This 
phenomenon could be explained by the adherence of the sticky polymers to the well 
surface. The value of cell viability that appeared was still larger compared to the visual 
inspection of viable cells under microscope (Fig. 3.9A, 3.9B). Until 42h, cells show 
more proliferation at lower dendrimer concentrations; at 72h and concentrations 
between 1-5 mg/ml, the dendrimer shows citotoxicity effects.   
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Figure 3.8. Cell Viability assessed by the four methods. (a) U251MG, (b) mMSCs.  
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Based on the above observations, trypan blue exclusion was used as the standard 
method to validate the cell viability data obtained by the above assays (Fig. 1 and  1). 
This method involved direct counting of viable cells and hence eliminated the 
possibility of interference from occurring. The results demonstrated a large difference 
between the cell viability data from trypan blue counting and all other three enzyme 
activity-based assays. These values correlated well with visual estimations when 
observing under the microscope. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Inverted microscope images (4X) of both cell lines after 72h incubation with and without the 
dendrimer. A) U251MG (a, control with no dendrimer; b, 0.5 mg/ml; c, 1 mg/ml; d, 5 mg/ml); B) mMSCs (a, 
control with no dendrimer; b, 0.5 mg/ml; c, 1 mg/ml; d, 5 mg/ml). Red arrows indicate the presence of cell 
accumulations (mMSCs-a) or holes in the monolayer.  
A 
b
c d
a a b
dc
B 
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Images of both cell lines at 72h of incubation show less cellular growth with higher 
dendrimer concentrations (Fig. 3.9Ac, 3.9Ad, 3.9Bc, 3.9Bd). In the case of mMSCs, 
cells that were incubated only with medium without dendrimer tend to form 
agglomerations (Fig. 3.9Ba), which is a sign of uncontrolled growth that ends in the 
cells differentiation and so, of their lost in multipotency.  
 
In order to measure the level of interference with CV, AB and MTT, the same assays 
were carried out, but incubating the cells with dendrimer and without reagents. 
Furthermore, dendrimer with assay reagents in the absence of cells were also analyze. 
No significant effect on absorbance or fluorescence readout was observed (data not 
shown). Therefore, the increased absorbance and fluorescence could appear due to a 
combination of cells, dendrimer and assay reagents. Also, the changes in the metabolic 
state of the cells could be implicated. There is evidence that for the AB assay, there is 
accumulation of colorless products with time of incubation, which can also affect the 
final results.   
 
To analyze whether culturing the cells with a different formulation of the dendrimer 
worked better in terms of citotoxicity and rate of proliferation, the dendrimer was 
incubated in gelatin in the bottom of the wells prior to seeding them, so they could grow 
on top of the monolayer gelatin-dendrimer. This way the dendrimer was intended to be 
more accessible, or for longer times to the cells, as it would be trapped in the gelatin.    
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There is no effect, neither positive nor negative, over any of the cell types when they 
grow on top of a dendrimer-gelatin monolayer (Fig. 3.10).  
Lastly, as the results indicate an increase in cell growth and cells grow “healthier” 
(Fig. 3.11) and with a better morphology (Fig. 3.9B) in the presence of the dendrimer, a 
comparison was made between the maximum absolute values of cellular growth 
achieved by culturing the cells in DMEM-Low Glucose and MesenCult both with 
Alamar Blue and MTT. The reason for this was to see whether the levels reached by 
cells growing in DMEM-LG in the presence of mPEG2000-G3-PAMAM matched or 
were similar to those reached by cells in MesenCult. If so, the expensive MesenCult 
medium could be substitute by normal DMEM with dendrimer. The analysis showed 
that the absolute values for cells in MesenCult (2.500 in MTT and 1200 in AB) were 
always well above those for cells in the presence of the dendrimer but when dendrimer 
is added only once. Further studies about the formulation should be done (1.000 in 
MTT and 600 in AB).  
 
 
 
 
 
 
 
 
 
 
In summary, our results suggest that the method of analysis for the level of 
citotoxicity matters. Taking together the results obtained with trypan blue, the 
interference assays and the images, we can conclude that, as expected, the level of 
biocompatibility of the PEG2000-G3-PAMAM dendrimer is high, showing citotoxicity for 
periods higher than 72 hours and concentrations above 5 mg/ml. Also, at lower 
incubation times (<24h) and low concentracions (0.5 mg/ml), the dendrimer could have 
a proliferation boosting effect that needs to be further investigated.  
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Figure 3.11. Cell Viability 
comparison. mMSCs growing 
in a basic DMEM-LG media 
(white) and in a enriched media 
(grey) analyzed by the AB 
method.  
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To get an insight into the cells replication state in the presence of mPEG2000-G3-
PAMAM, cell cycle analyses were performed. This approach reveals distribution of 
cells in three major phases of the cycle (Fig. 1), where quiescent and G1 cells will have 
one copy of DNA and will therefore have 1X fluorescence intensity. Cells in G2/M 
phase of the cell cycle will have two copies of DNA and accordingly will have 2X 
intensity. Since the cells in S phase are synthesizing DNA they will have fluorescence 
values between the 1X and 2X populations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The dendrimer at concentrations up to 1 mg/ml has a minor impact in the growth and 
proliferation of mMSCs. As compared with the control, when cells were exposed to 1 
mg/ml of the dendrimer for 72h the number of cells following the normal cell cycle is 
practically the same (Fig. 3.13). Most of the cells remain in the G1 phase (96.05% and 
91.32%), which indicates cell growth and proliferation. There is a small variation in the 
number of cells that are in S phase, which increases from 1.20% (control) to 3.21% 
(mMSCs incubated with the dendrimer) and also on the number of cells in phase G2/M 
from 2.74% to 5.46%. These results may suggest a slighter stimulation of division of the 
cells in the presence of the dendrimer which can explain the enhancement on the 
cellular growth.   
 
 
Figure 3.12. Cell cycle. When not in the 
process of preparing for cell division, cells 
remain in the G1 portion of the cell cycle 
(synthetic growth phase). The G2 phase is a 
time for repair of any DNA damage which has 
occurred during the preceding cell cycle 
phases, and for the reorganization of the DNA 
structure which must take place before the 
DNA can be divided equally between 
daughters during Mitosis.In the S phase they 
have a DNA content just barely above their 
starting G1 content and increases 
progressively until they complete the S phase 
with the G2 DNA content (Barry,7). 
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Mesenchymal stem cells are multipotent cells in nature and have the unique ability to 
differentiate into various cell types among which osteogenic and adipogenic 
differentiation are considered as hallmarks. Therefore, to confirm that the dendrimer 
doesn’t affect the identity of the cells, CD34, CD73 and CD105 cell surface markers, 
and adipogenic differentiation potential were evaluated.  
The majority of the cells both in the presence and absence of dendrimer expressed 
high levels of CD73 and CD105 (Fig, 3.14A and 3.14B), although the marker CD34 
displayed low or very little expression (Fig, 3.14A and 3.14B). The lower intensity 
coming from the markers of the cells incubated with the dendrimer is due to the lower 
amount of total cells compare with the control cells.  
mMSCs were incubated in adipogenic differentiation medium to identify the 
multipotency character. One week after adipogenic induction, formation of intracellular 
lipid vacuoles were detected in these cells. Thereafter, lipid accumulation increased 
along with the inductive periods, which was chemically stained by Oil Red O, a specific 
staining, which identifies lipid droplets in adipocytes, thereby, confirming adipocytic 
nature of these cells after 14 days (Fig. 3.14C).  
 
Figure 3.13. Histogram showing the cell cycle phase distribution of mMSCs cultured for 
72h with 1 mg/ml of mPEG2000-G3-PAMAM in comparison with the control group. The 
X-axis shows the intensity of the detected signal and the Y-axis measures the number of 
events (cells) counted.  
Channels (Yellow-A-PI Yellow-A)
0 30 60 90 120 150
N
u
m
be
r
0
50
0
10
00
15
00
20
00
mMSCs 
(Ctr) 
mMSCs + 
mPEG2000-G3-PAMAM
(1 mg/ml)
G2: 5.46 %
Channels (Yellow-A-PI Yellow-A)
0 30 60 90 120
N
u
m
be
r
0
50
0
10
00
15
00
20
00
S: 1.20 %
a b 
G1: 96.05 %
G2: 2.74 %
G1: 91.32%%
S: 3.21 %
N
u
m
be
r
0
50
0
10
00
15
00
20
00
N
u
m
be
r
0
50
0
10
00
15
00
20
00
PAMAM-based Dendrimers for Diverse Biomedical Applications 
 
 45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14. Effect of mPEG2000-G3-PAMAM dendrimer on the multipotent 
characteristics of mMSCs. (A) and (B) Characterization of MSCs by flow cytometry. 
Antibodies used for these experiments were anti-CD73 (PE), anti-CD105 (FITC) as positive 
controls and anti-CD34 (PE) as negative control. The X and Y-axes measure the different 
emissions, displaying a dot for each of the cells that show that particular emission. Analysis 
with flow cytometer showed that over 95% cells of the mMSCs populations were positive for 
both CD73 and CD105 (specific surface markers of MSCs) and negative for CD34, thus 
confirming their identity as MSCs. (C) Adipogenic differentiation of cultured MSCs was 
confirmed by Oil-red O staining. MSCs were cultured in appropriate induction media in the 
absence (a) or presence (b) of 1 mg/ml of dendrimer added at different times of the process, 
differentiate normally (more time is required for fully differentiation of the monolayer) 
mMSCs + mPEG2000-G3-PAMAM
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CONCLUSIONS   
In this study we work with a mPEG2000 modified G3-PAMAM dendrimer. This 
dendrimer was selected on an attempt to find equilibrium between high toxicity to the 
host cells and more efficiency towards delivery and killing pathogens. We use a 
PAMAM dendrimer because it has been previously demonstrated that they are widely 
used for different biomedical applications and they are readily commercially available. 
There is evidence that lower generations (as ours) of this PAMAM dendrimers are more 
efficient towards killing bacteria and delivering DNA than higher generations and there 
are less citotoxic. We though of this specific dendrimer as it could have further 
applications in the near future as the delivery of viral vectors as well. Lastly, 
modification of the external groups with PEG2000 makes the dendrimer more 
biocompatible (compared to longer PEG chains).  
 
In this work we have given good proof that the PAMAM dendrimer completely 
covered with PEG is highly biocompatible (~1mg/ml) and doesn’t affect the phenotypic 
characteristics or the differentiation potential of the cell types tested. On the other hand, 
this modification shields the positive charges of the dendrimer and so its ability to 
attach molecules such as DNA working as therapeutic agents is very limited. In this 
line, although some activity is retained, the dendrimer has a lowered potential as 
antimicrobial.  
 
For future works, a more effective vector should be used that contains a lower degree 
of PEGylation, being more toxic to bacteria, but that still could be used at high 
concentrations with cells and would have enough external charge for attachment of 
molecules for gene delivery.   
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